NM-SCEYE
15.6.2022 16:53:08 CEST | Business Wire | Press release
Sceye, a manufacturer of High-Altitude Platform Stations (HAPS), announced today that it reached the stratosphere with the aim of demonstrating the ability to stay over an area of operation for months at a time using renewable energy sources. The milestone test launch, which is using patented solar and battery power, puts Sceye on track to expand internet access to remote populations, monitor greenhouse gasses down to individual emitters, and detect natural disasters as they begin. The company also announced additional test flights for Q3 and Q4 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614006039/en/
Sceye’s HAPS launched at 6:55 AM MDT from the company’s hangar at the Roswell International Airport.
“Today’s test flight holds extraordinary potential for stratospheric discovery,” said Sceye founder and CEO, Mikkel Vestergaard Frandsen. “By maintaining position in the stratosphere for extended periods of time, we can begin realizing the promises of the stratosphere for life on Earth. Universal internet access, methane monitoring, and wildfire detection are all at our fingertips.”
Today’s launch objectives were to:
- Test durability and performance of renewable power systems in the stratosphere
- Demonstrate the ability to stay over an area of operation
- Maintain a constant float altitude in the stratosphere
Sceye’s HAPS design, in the form of an enhanced balloon, can lift a variety of payloads for connectivity, earth observation, and scientific research. Its hull fabric can manage the extreme environment of the stratosphere, and optimizes strength, helium retention, and thermal management. High-performance batteries and solar panels close the power loop: enough power storage to last until sunrise, and efficient solar cells to collect energy during the day.
“We are thrilled to see years of research and development culminating in this milestone moment,” said David Kim, Sceye’s Chief Technology Officer. “It is the very best application of material science pushing the boundaries of near space.”
Chief of Mission Operations, Stephanie Luongo, said, “This launch is the second of six in our test program this year intended to verify payload and automated flight while ensuring safe operations. We’re excited to learn more from upcoming flight tests planned for late summer and fall.”
In October 2021, Sceye was the first to connect a Massive MIMO antenna with 3D beamforming from the stratosphere directly to smartphones on the ground over a 140 km distance — a world record in Open RAN. In March 2022, Sceye successfully validated its automated flight software which increases the reliability of its HAPS during its most critical phases of flight – launch and ascent.
Sceye has partnered with the U.S. Environmental Protection Agency (EPA), New Mexico Economic Development Department, and New Mexico Environment Department on a five-year study to monitor air quality in the State of New Mexico. Sceye’s HAPS will track methane emissions with a sub 1-m resolution, allowing them to determine pollution levels as well as pinpoint individual emitters.
About Sceye
Sceye is a material science company founded in 2014 to unleash the possibilities in the stratosphere by uplifting and connecting all people, and protecting our planet. The company has developed a new generation of stratospheric platforms to provide universal and equitable connectivity, improve climate change monitoring, natural resource stewardship, forest fire monitoring and better detect and contain disasters before they spiral out of control.
Sceye continues the humanitarian work of founder and CEO Mikkel Vestergaard Frandsen. As owner and former CEO of the public health companies Vestergaard and LifeStraw, he led innovations in material science that have saved millions of lives. LifeStraw water filters have helped nearly eradicate Guinea worm disease, and PermaNet, bed nets made from innovative fibers that release microscopic doses of insecticide, have helped reduce global malaria deaths by more than half.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614006039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
